Adherence to Surveillance Endoscopies Posteradication of Barrett's Esophagus With High-grade Dysplasia or Carcinoma In Situ

J Clin Gastroenterol. 2023 May-Jun;57(5):459-465. doi: 10.1097/MCG.0000000000001701. Epub 2022 Apr 8.

Abstract

Goals: We aimed to evaluate factors associated with patient adherence to recommended surveillance guidelines during the first 3 years after endoscopic eradication of Barrett's esophagus (BE) with high-grade dysplasia (HGD) or T1a carcinoma in situ (CIS) and the relationship between adherence and detection of recurrence.

Background: While surveillance endoscopies after treatment of BE with HGD or T1a CIS are an important component of therapy, it is unclear whether these high-risk patients are adhering to recommended surveillance guidelines.

Materials and methods: A total of 123 BE patients who underwent radiofrequency ablation±endoscopic mucosal resection for biopsy-proven HGD, or CIS between January 2010 and November 2018 underwent retrospective review for adherence to surveillance guidelines, patient factors related to adherence, and recurrence of dysplasia or CIS at 12, 24, and 36 months.

Results: Of 123 BE patients (89 HGD and 34 CIS), adherence during the first year following treatment was 26.97% for HGD patients and 41.18% for CIS patients, with increasing adherence rates in subsequent years. Patients who received 3 to 4 surveillance endoscopies in the first year posttreatment had significantly higher rates of recurrence detection than patients who received 0 to 2 surveillance endoscopies over this interval ( P =0.01). No patient factors were found to impact adherence significantly.

Conclusions: Adherence to recommended surveillance intervals after endoscopic treatment of BE with HGD or CIS is low, with poor adherence during the first year associated with decreased detection of recurrence. Future studies are needed to evaluate risk factors and develop a potential intervention for poor adherence in this high-risk population.

MeSH terms

  • Barrett Esophagus* / complications
  • Barrett Esophagus* / diagnosis
  • Barrett Esophagus* / surgery
  • Carcinoma in Situ* / complications
  • Carcinoma in Situ* / diagnosis
  • Carcinoma in Situ* / surgery
  • Esophageal Neoplasms* / diagnosis
  • Esophageal Neoplasms* / pathology
  • Esophageal Neoplasms* / surgery
  • Esophagoscopy / adverse effects
  • Humans
  • Hyperplasia / complications
  • Precancerous Conditions* / pathology